SCHEMBL6533795

SCHEMBL6533795

COc1ccccc1-c1nc(Cl)c2ccc(C)cc2n1.COc1ccccc1-c1nc(NCc2nnc(C)o2)c2ccc(C)cc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 15/20 0.50
CYP2D6 P10635 15/20 0.50
CYP3A4 P08684 14/20 0.50
CYP2C19 P33261 11/20 0.50
TSHR P16473 9/20 0.50
HSD17B10 Q99714 8/20 0.50
LMNA P02545 8/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
MAPK1 P28482 4/20 0.50
ALOX15 P16050 7/20 0.49
USP2 O75604 6/20 0.49
CLK4 Q9HAZ1 5/20 0.48
MAPT P10636 2/20 0.47
ALDH1A1 P00352 8/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
KDM4E B2RXH2 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
HPGD P15428 2/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939227 0.95 CYP1A2 (0.55) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL1084710 0.81 KMT2A (0.52) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL938993 0.81 CYP1A2 (0.40) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL183879 0.81 CYP1A2 (0.48) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL938995 0.75 CYP1A2 (0.53) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL3910814 0.71 ELANE (0.58) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL1084308 0.70 MEN1 (0.50) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL8344637 0.70 CYP1A2 (0.50) CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL183703 0.68 PTGES (0.39)
SCHEMBL1084998 0.68 CYP1A2 (0.65) CYP1A2CYP2D6CYP3A4CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608632-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2005-12-28 EP disclosed
US-20040248890-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2004-12-09 US disclosed
WO-2004078733-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248890-A1 Quinazolines useful as modulators of ion channels KCNN3, KCNN2, CACNA1I CYP1A2 2515/4885CYP2D6 2468/4885CYP3A4 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.